Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Gene therapy success in the laboratory buoys hope for Parkinson’s disease

11.10.2002


Scientists at Jefferson Medical College have used gene therapy to reverse the progression of Parkinson’s disease in rats. They have found that by adding a gene for an enzyme, they were able to reprogram brain circuitry and halt the deterioration of dopamine producing brain cells, one of the key problems in the disease.



“It’s not just inserting a replacement for a missing or mutated gene as a treatment for a genetic disorder,” says Michael Oshinsky, Ph.D., research assistant professor of neurology at Jefferson Medical College of Thomas Jefferson University in Philadelphia and part of the team reporting its results October 11 in the journal Science. “This is more profound. We are actually changing the brain’s circuitry as treatment for a disease.”

According to Dr. Oshinsky and Jia Luo, M.D., research associate at Jefferson Medical College of Thomas Jefferson University, in Parkinson’s, a portion of the brain called the subthalamic nucleus is overactive. These cells produce glutamate, an excitatory neurotransmitter, or chemical message carrier, into another region called the substantia nigra, which is important for the coordination of movement and where the brain chemical dopamine is made. Parkinson’s is caused by the deterioration of dopamine-producing nerve cells.


The researchers – including scientists from Jefferson, the University of Auckland, New Zealand, and Cornell University – took their cues from work with deep brain stimulation, where brain cells in the subthalamic nucleus are stimulated at a high frequency as a treatment for late-stage Parkinson’s. This treatment prevents overactivity in the substantia nigra.

The team, led by Matthew During, M.D., formerly of Jefferson Medical College of Thomas Jefferson University and now at the University of Auckland, decided that instead of turning off the neurons in the subthalamic nucleus, they would attempt to change the neurons from excitatory to inhibitory, which would then contain the inhibitory chemical messenger GABA.

The team used an adeno-associated virus to carry the gene for an enzyme, glutamic acid decarboxylase (GAD), into brain cells in rats that were made Parkinsonian. They saw a dramatic difference in the behavior and physiology of the Parkinsonian rats treated with the GAD-carrying virus compared to the Parkinsonian rats that did not receive the treatment.

Three weeks after the gene transfer, Dr. Luo made Parkinson’s lesions on one side of the brains of rats that had the gene therapy. The researchers then performed various behavioral tests to see if the gene therapy could protect against the development of classic Parkinson’s symptoms. One test showed that nearly 70 percent of the animals with Parkinson’s lesions and the GAD gene therapy had no Parkinson’s symptoms when they received chemicals that mimicked dopamine in the brain. Normally, animals with Parkinson’s are hypersensitive to dopamine, and actually respond to it by running around in circles over and over. The test result was a “very strong behavioral measure showing this is a good treatment for Parkinson’s,” Dr. Oshinsky says.

The researchers also stimulated the rats’ subthalamic nucleus and examined the resulting connection in the substantia nigra. They compared animals that had received the GAD gene therapy with those that had not had the gene therapy and normal rats. In the untreated Parkinsonian rats, more than 80 percent of cells showed excitatory responses. As few as 10 percent showed inhibitory responses.

But in the GAD-treated animals, they found practically the opposite. Nearly 80 percent of the neurons they recorded signals from showed inhibitory responses, whereas only about 17 percent showed excitatory responses. “It was a profound change in the connection between the subthalamic nucleus and the substantia nigra – that’s where there was a phenotypic change in the neural connections,” Dr. Oshinsky explains.

“By reprogramming it [the brain’s circuitry], we actually could show that it was protecting dopamine neurons from dying off,” Dr. During says. “The main advantage is that inhibitory input seems to protect the dopamine neurons.”

“It’s a classic excitatory connection in the brain and we converted it to an inhibitory connection,” Dr. Oshinsky says. “It’s nice to be able to show a real mechanism of action for a potential treatment of Parkinson’s.” He notes that the rats were tested as many as 10 months after receiving gene therapy; the change was permanent. The group already has approval from the Food and Drug Administration for a clinical trial, which will be the first gene therapy protocol for Parkinson’s disease.

Steve Benowitz | EurekAlert!
Further information:
http://www.tju.edu/

More articles from Health and Medicine:

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

nachricht Flexible sensors can detect movement in GI tract
11.10.2017 | Massachusetts Institute of Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Ocean atmosphere rife with microbes

17.10.2017 | Life Sciences

Neutrons observe vitamin B6-dependent enzyme activity useful for drug development

17.10.2017 | Life Sciences

NASA finds newly formed tropical storm lan over open waters

17.10.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>